Saluda Medical

Saluda Medical is a medical technology company based in Sydney, Australia, founded in 2013. The company focuses on advanced neuromodulation therapies for spinal cord treatment, particularly in managing chronic pain. Saluda Medical is recognized for its innovative approach, being the first to measure the spinal cord's physiological response to stimulation using Evoked Compound Action Potentials (ECAPs). This technology enables their closed-loop spinal cord stimulation (SCS) system to adjust therapy in real time, enhancing pain relief outcomes. The flagship product, the Evoke® SCS System, is designed to provide consistent and effective pain relief by monitoring and adjusting stimulation based on real-time feedback. The company also offers the Clarity® Programming Application, which enhances the customization of neuromodulation therapy. Saluda Medical has achieved significant clinical milestones, including published data in prestigious journals and multiple regulatory approvals, including FDA and CE Mark. The company has received numerous awards for its innovative products and is recognized as a leading healthcare startup in Australia.

• Employees 480
• Founded 2011
• Annual Revenue $20000000
• Total Funding $499527549